Drugs / HL-300
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07684937 | Jun → Nov 2024 | atopic eczema | Hangzhou Highlightll Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07629778 | May 2026 → Jun 2027 expected | atopic eczema | Hangzhou Highlightll Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HL-300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07684937 ↗ |
| Route | Topical | “topical administrations” NCT07684937 ↗ |